A phase I study investigated the feasibility of universal CD19/CD22-targeting CAR-T cells with a CRISPR/Cas9-disrupted TRAC and CD52 gene in six patients with R/R ALL. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.